01 Jun 2026

CRC Research Update — June 01, 2026

Creator: The CRC Digest
Published: 2026-06-01T18:06:08Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Encorafenib + cetuximab + FOLFIRI evaluated in BRAF V600E-mutant metastatic colorectal cancer
In the phase 3 BREAKWATER Cohort 3 trial, 147 previously untreated patients with BRAF V600E-mutant mCRC were randomized to receive encorafenib + cetuximab + FOLFIRI or FOLFIRI with or without bevacizumab; the primary endpoint was objective response rate by blinded independent central review, and the key secondary endpoint was progression-free survival by blinded independent central review. (Annals of Oncology)
Adding nivolumab to encorafenib-cetuximab tested in MSS BRAF V600E mCRC
SWOG S2107, a randomized phase 2 trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAF V600E metastatic colorectal cancer, was presented. (Journal of Clinical Oncology)
Screening test preferences vary by sociodemographic factors in underserved populations
A survey of 1,014 adults aged 45-75 across community health centers found that preferences for stool test, blood test, and colonoscopy varied by sociodemographic factors and health beliefs, highlighting the need to understand screening preferences in populations with low screening rates. (Digestive Diseases and Sciences)

🧬 Biomarker Spotlight

Research by genetic subtype — BRAF, MSI-H, and more

BRAF V600E triplet regimen advances in phase 3 trial
BREAKWATER Cohort 3 evaluated encorafenib + cetuximab + FOLFIRI versus FOLFIRI ± bevacizumab in previously untreated BRAF V600E-mutant mCRC, with primary endpoint of objective response rate and key secondary endpoint of progression-free survival. (Annals of Oncology)

Stay informed as research continues to advance treatment options across biomarker subtypes and stages.

CRC Research Update

Subscribe to The CRC Digest